| Literature DB >> 30020428 |
Nadia Bougarne1,2, Basiel Weyers1,2, Sofie J Desmet1,2, Julie Deckers3,4, David W Ray5, Bart Staels6,7,8,9, Karolien De Bosscher1,2.
Abstract
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of clinical interest as a drug target in various metabolic disorders. PPARα also exhibits marked anti-inflammatory capacities. The first-generation PPARα agonists, the fibrates, have however been hampered by drug-drug interaction issues, statin drop-in, and ill-designed cardiovascular intervention trials. Notwithstanding, understanding the molecular mechanisms by which PPARα works will enable control of its activities as a drug target for metabolic diseases with an underlying inflammatory component. Given its role in reshaping the immune system, the full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30020428 DOI: 10.1210/er.2018-00064
Source DB: PubMed Journal: Endocr Rev ISSN: 0163-769X Impact factor: 19.871